First National Bank & Trust Co. of Newtown Has $963,000 Stake in Baxter International Inc. (NYSE:BAX)

First National Bank & Trust Co. of Newtown trimmed its position in shares of Baxter International Inc. (NYSE:BAX) by 2.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 24,929 shares of the medical instruments supplier’s stock after selling 500 shares during the period. First National Bank & Trust Co. of Newtown’s holdings in Baxter International were worth $963,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BAX. Headinvest LLC purchased a new stake in Baxter International in the 3rd quarter valued at $25,000. Bruce G. Allen Investments LLC purchased a new stake in Baxter International in the 4th quarter valued at $36,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Baxter International in the 4th quarter valued at $37,000. CKW Financial Group purchased a new stake in Baxter International in the 4th quarter valued at $43,000. Finally, BKM Wealth Management LLC purchased a new stake in Baxter International in the 4th quarter valued at $44,000. 90.19% of the stock is owned by institutional investors and hedge funds.

Baxter International Stock Performance

Shares of BAX stock traded up $0.04 on Friday, hitting $39.69. 613,358 shares of the stock were exchanged, compared to its average volume of 3,653,423. The company has a current ratio of 1.48, a quick ratio of 1.04 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $20.16 billion, a PE ratio of 7.59, a P/E/G ratio of 2.13 and a beta of 0.62. Baxter International Inc. has a one year low of $31.01 and a one year high of $50.21. The firm’s 50 day moving average is $41.80 and its two-hundred day moving average is $38.40.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.02. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.81 billion. Baxter International had a return on equity of 19.49% and a net margin of 17.77%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.88 EPS. Sell-side analysts expect that Baxter International Inc. will post 2.89 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a dividend of $0.29 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.16 annualized dividend and a dividend yield of 2.92%. Baxter International’s payout ratio is 22.22%.

Analyst Ratings Changes

A number of research firms recently commented on BAX. Citigroup increased their price target on Baxter International from $41.00 to $44.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Barclays increased their price target on Baxter International from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Monday, February 12th. UBS Group reduced their price objective on Baxter International from $40.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 6th. JPMorgan Chase & Co. upped their price objective on Baxter International from $38.00 to $44.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Finally, Bank of America upped their price objective on Baxter International from $42.00 to $45.00 and gave the company a “neutral” rating in a research note on Tuesday, March 5th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $46.30.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.